Cartilage destruction and bone erosion in arthritis: The role of tumour necrosis factor α

Annals of the Rheumatic Diseases

Volumn 59, Issue SUPPL. 1, 2000, Pages

  Williams, R O ^a   Feldmann, M ^a   Maini, R N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CD4 IMMUNOGLOBULIN; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BONE EROSION; CARTILAGE DEGENERATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CARTILAGE, ARTICULAR; CD4-POSITIVE T-LYMPHOCYTES; COLLAGEN; DISEASE MODELS, ANIMAL; HUMANS; MICE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033768311     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
2. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
3. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
4. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage
5. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
6. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors
7. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor
8. Stimulation of endothelial cell binding of lymphocytes by tumor necrosis factor
9. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint
10. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-α
11. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity
12. Collagen arthritis as a relevant model for rheumatoid arthritis: Evidence pro and con
13. Autoimmunity to type II collagen an experimental model of arthritis
14. Immunisation against heterologous type II collagen induces arthritis in mice
15. Induction of arthritis in monkeys by immunization with type II collagen
16. Homologous type II collagen induces chronic and progressive arthritis in mice
17. Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis
18. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice
19. Anti-tumor necrosis factor ameliorates joint disease in murine collagen -induced arthritis
20. Evolution of collagen arthritis in mice is arrested by treatment with anti -tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
21. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors
22. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice
23. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4
24. Rodent models of arthritis: Relevance for human disease
25. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis
26. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment
27. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra
28. Role of TNFα in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralising monoclonal antibodies
29. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis
30. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice
31. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis
32. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
33. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice
34. DBA/1 mice expressing the human TNF-α transgene develop a severe, erosive arthritis: Characterisation of the cytokine cascade and cellular composition
35. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA)
36. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice
37. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α
38. Treatment with a chimaeric monoclonal antibody to tumour necrosis factor α suppresses disease activity in rheumatoid arthritis: Results of a multi-centre, randomised, double blind trial
39. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis
40. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
41. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
42. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
43. Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis
44. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
45. Predominantly T-cell infiltrate in rheumatoid synovial membranes
46. Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis
47. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
48. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis
49. Biologic agents for treating rheumatoid arthritis
50. Effect of antithymocyte serum on collagen arthritis in rats: Evidence that T cells are involved in its pathogenesis
51. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG
52. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction
53. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
54. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis
55. A comparative study into the mechanisms of action of anti-TNFα, anti-CD4 and combined anti-TNFα/anti-CD4 treatment in early collagen-induced arthritis
56. Neutralization of interleukin- 1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response
57. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data